Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum
Use
The test is useful for distinguishing primary from secondary membranous nephropathy cases with antibodies against THSD7A. Recently, autoantibodies against phospholipase A2 receptor (PLA2R) in the kidney were determined to be the major target antigen for patients with idiopathic/primary membranous nephropathy. Approximately 70% of patients with primary MN circulate anti-PLA2R antibodies, and in the remaining 30% who are PLA2R-negative, anti-thrombospondin type-1 domain-containing 7A (THSD7A) was shown to have approximately a 10% prevalence (or about 3% of all primary MN patients). THSD7A has been described as a potential tumor antigen, suggesting that THSD7A-positive patients merit a thorough cancer screening.
Special Instructions
Not provided.
Limitations
A diagnosis of primary or secondary membranous nephropathy (MN) should not be made based on a single test result. The clinical symptoms, results on physical examination, and laboratory tests (eg, serological tests), when appropriate, should always be taken into account when considering the diagnosis of primary versus secondary MN. Absence of circulating autoantibodies does not rule out a diagnosis of primary MN.
New York Approved
Methodology
Immunoassay (IFA)
Biomarkers
THSD7A
Protein
LOINC Codes
- 93339-0 - THSD7A IgG SerPl Ql IF
- 93339-0 - THSD7A IgG SerPl Ql IF
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial within 2 hours of collection.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |